What alternative therapy should be given to a patient with persistent constipation despite Amitiza (lubiprostone)?

Switch to Linaclotide, Plecanatide, or Prucalopride

For a patient with persistent constipation despite Amitiza (lubiprostone), switch to linaclotide, plecanatide, or prucalopride—all carry strong recommendations with moderate-quality evidence and are superior alternatives to continuing ineffective therapy. 1

Recommended Next-Line Agents

The 2023 AGA-ACG guidelines provide clear direction when lubiprostone fails in chronic idiopathic constipation:

First-Tier Alternatives (Strong Recommendations)

Linaclotide (Recommendation 8):

• Strong recommendation, moderate certainty evidence 1
• Can replace or be added to lubiprostone
• Studied for 12 weeks in trials with no duration limit on the drug label
• Main caveat: Diarrhea may occur and lead to discontinuation
• Mechanism: Guanylate cyclase-C agonist that increases intestinal fluid secretion

Plecanatide (Recommendation 9):

• Strong recommendation, moderate certainty evidence 1
• Similar profile to linaclotide—can replace or augment current therapy
• Also studied for 12 weeks with no label duration limit
• Main caveat: Diarrhea risk similar to linaclotide
• Mechanism: Also a guanylate cyclase-C agonist

Prucalopride (Recommendation 10):

• Strong recommendation, moderate certainty evidence 1
• Studied for 4-24 weeks, no duration limit on label
• Can replace or be added to existing regimen
• Main caveats: May cause headache, abdominal pain, nausea, and diarrhea
• Mechanism: Selective 5-HT4 receptor agonist that enhances colonic motility

Clinical Decision-Making Algorithm

Choose based on patient-specific factors:

1. If abdominal pain is prominent: Favor linaclotide or plecanatide—these secretagogues address both constipation and abdominal discomfort more effectively than lubiprostone alone 2

2. If diarrhea risk is concerning: Consider prucalopride first, as it has a different mechanism (prokinetic vs. secretagogue) and may have less diarrhea risk

3. If cost/insurance is a barrier: All three are prescription agents with similar cost profiles; check formulary coverage

4. If nausea was the limiting factor with lubiprostone: Any of these three alternatives have different side effect profiles and should be better tolerated

Why These Over Lubiprostone

Lubiprostone carries only a conditional recommendation with low certainty evidence (Recommendation 7) 1, while all three alternatives have strong recommendations with moderate certainty evidence. This represents a meaningful upgrade in evidence quality and expected efficacy.

Common Pitfalls to Avoid

• Don't simply increase lubiprostone dose: The FDA label already recommends 24 mcg twice daily for CIC 33, and nausea is dose-dependent—escalation will likely worsen tolerability without improving efficacy

• Don't add stimulant laxatives as monotherapy: While bisacodyl and senna have roles as rescue therapy 1, they don't address the underlying pathophysiology as effectively as the prescription secretagogues or prokinetics

• Don't forget to take with food: If you do retry lubiprostone at any point, emphasize taking with food and water to reduce nausea 3

• Monitor for diarrhea with new agents: All three alternatives can cause diarrhea; counsel patients to report severe diarrhea and consider dose reduction if it occurs

Implementation Strategy

Start with one of the three strong-recommendation agents based on the patient's symptom profile and concerns. If the first alternative fails after an adequate trial (typically 4-12 weeks), consider switching to one of the other two strong-recommendation options or combining agents from different classes 2. The evidence supports both replacement and adjunctive strategies 1.